Почетна › Hronična limfocitna leukemija › Северна Каролина
Kliničke studije za Hronična limfocitna leukemija u državi Северна Каролина
35 studija za Hronična limfocitna leukemija traži učesnike na lokacijama u državi Северна Каролина.
Gradovi u državi Северна Каролина
- Durham28 студија
- Winston-Salem9 студија
- Charlotte9 студија
- Greenville5 студија
- Asheville4 студија
- Goldsboro3 студија
Zvanični tekst studije (na engleskom)
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
- GC2202 Study Site 109, Greenville
- GC2202 Decentralized Study Site 114, Morrisville
- GC2202 Study Site 117, Wilson
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT05645107Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Southeastern Medical Oncology Center-Clinton, Clinton
- Duke University Medical Center, Durham
- и још 5
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT04269902ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
- Duke Adult Blood and Marrow Clinic, Durham
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT07342478A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- East Carolina University, Greenville
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06588478Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- AdventHealth Infusion Center Asheville, Asheville
- Southeastern Medical Oncology Center-Clinton, Clinton
- AdventHealth Infusion Center Haywood, Clyde
- и још 6
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
Узраст од 40 до 75 · Оба пола · Ажурирано 4. 11. 2026. · NCT05334069Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Duke University Medical Center, Durham
- Margaret R Pardee Memorial Hospital, Hendersonville
Тражи се учесникФаза 3
Узраст 65 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07321652A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Duke University, Durham
- Novant Health Cancer Institute, Winston-Salem
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07221500A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Durham VA Medical Center, Durham, NC, Durham
Тражи се учесникФаза 2
Узраст од 18 до 80 · Оба пола · Ажурирано 30. 10. 2026. · NCT06520098A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Research Site, Charlotte
- Research Site, Charlotte
- Research Site, Winston-Salem
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT06564038Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
Тражи се учесникОпсервациона студија
Узраст од 18 до 120 · Оба пола · Ажурирано 28. 10. 2026. · NCT01137643Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill
Тражи се учесникФаза 1/2
Узраст од 13 до 90 · Оба пола · Ажурирано 26. 10. 2026. · NCT06533579MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab
- Research Site, Charlotte
- Research Site, Durham
- Research Site, Winston-Salem
Тражи се учесникФаза 2
Узраст од 18 до 130 · Оба пола · Ажурирано 23. 10. 2026. · NCT07024706A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- University of North Carolina At Chapel Hill, Chapel Hill
- Levine Cancer Center, Charlotte
- Atrium Health Wake Forest Baptist, Winston-Salem
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 23. 10. 2026. · NCT06943872Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
- The University of North Carolina at Chapel Hill, Chapel Hill
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 21. 10. 2026. · NCT06043674Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Duke University, Durham
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 14. 10. 2026. · NCT07648264A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Carolina Oncology Specialists, PA ( Site 0054), Charlotte
- Southeastern Medical Oncology Center ( Site 0049), Goldsboro
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT06136559Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 6. 10. 2026. · NCT07061951A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Research Site, Charlotte
- Research Site, Winston-Salem
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 30. 9. 2026. · NCT06542250A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Atrium Health Levine Cancer Institute (Lci), Charlotte
- Duke University Medical Center, Durham
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 28. 9. 2026. · NCT07277231A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- University of North Carolina At Chapel Hill, Chapel Hill
- Atrium Health Levine Cancer Institute (Lci), Charlotte
- Duke University Medical Center, Durham
- и још 1
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 28. 9. 2026. · NCT06973187Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- UNC School of Medicine, Division of Hematology, Chapel Hill
Тражи се учесникФаза 1/2
Узраст 12 и старији · Оба пола · Ажурирано 3. 9. 2026. · NCT04588922A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
- University of North Carolina at Chapel Hill, Chapel Hill
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 31. 7. 2026. · NCT06708897A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Duke University Medical Center, Durham
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 2. 7. 2026. · NCT05131022Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
- North Carolina Basnight Cancer Hospital, Chapel Hill
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 1. 7. 2026. · NCT06860880Registry of Older Patients With Cancer
- Seby B. Jones Cancer Center, Boone
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
- East Carolina University, Greenville
- и још 4
Тражи се учесникОпсервациона студија
Узраст 65 и старији · Оба пола · Ажурирано 29. 6. 2026. · NCT01137825Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of North Carolina, Chapel Hill
Тражи се учесникФаза 1
Узраст 13 и старији · Оба пола · Ажурирано 5. 5. 2026. · NCT04771572The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
- Wake Forest Baptist Health, Winston-Salem
Тражи се учесникОпсервациона студија
Узраст од 18 до 120 · Оба пола · Ажурирано 13. 4. 2026. · NCT01890486A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Atrium Health /ID# 267219, Charlotte
- Atrium Health Wake Forest Baptist Medical Center /ID# 273142, Winston-Salem
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 9. 4. 2026. · NCT06428019A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Duke University Medical Center, Durham
Тражи се учесникФаза 4
Узраст 18 и старији · Оба пола · Ажурирано 2. 3. 2026. · NCT06876649A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Duke University Medical Center, Durham
Тражи се учесникФаза 4
Узраст 18 и старији · Оба пола · Ажурирано 2. 3. 2026. · NCT06876662Study of SGR-1505 in Mature B-Cell Neoplasms
- Duke University, Durham
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 13. 2. 2026. · NCT05544019Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
- University of North Carolina /ID# 233313, Chapel Hill
- Novant Health Presbyterian Medical Center /ID# 230201, Charlotte
- Novant Health Forsyth Medical Center /ID# 249533, Winston-Salem
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 9. 2. 2026. · NCT04895436AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Duke University, Durham
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 10. 12. 2025. · NCT05602363A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- University of North Carolina, Chapel Hill
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 2. 10. 2025. · NCT05780034CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
- Duke University, Durham
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 17. 7. 2025. · NCT04704323Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.